Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pulling the Pfizer EUA would remove the only COVID-19 vaccine approved for all children from the US market. The Moderna ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

The Food and Drug Administration is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency’s top ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

A detailed analysis reveals one of the reasons the R21/Matrix-M malaria vaccine works so well: the antibodies generated ...

The company announced the vaccine's efficacy was 91% in "high-risk" populations. Novavax researchers also took a close look at sequencing data for 54 of the 77 Covid-19 cases in the study.

GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate ...